Javascript must be enabled to continue!
Abstract 2340: Disentangling the Myc:Max from the Mad:Max network
View through CrossRef
Abstract
The Myc family comprises three basic helix loop helix leucine zipper (bHLHLZ) transcription factors - C-myc, N-myc and L-myc - which regulate a plethora of intra and extracellular processes. Myc, when bound to Max, another bHLHLZ transcription factor, is able to bind specific DNA sequences, recruit coactivator complexes and promote transcriptional activation. Max can also promote transcriptional repression by dimerizing with distinct transcription factors such as Mad. Previous work has shown that Myc expression promotes proliferation whereas Mad expression leads to differentiation, implying that Myc and Mad have opposing roles in cells. Myc and Mad share the same heterodimeric partner, Max, suggesting that the cell proliferation/differentiation fate is determined by a Myc:Max:Mad network. To understand how this equilibrium is maintained, we are investigating the effects of separating the Myc:Max from the Mad:Max network. To separate these networks we have made use of specific Myc and Max mutant proteins in which reciprocal exchanges at the e and g positions of the leucine zipper have been introduced. Whereas the MycEG and MaxEG proteins dimerize with each other they are unable to associate with their wild type counterparts. Using these mutants we will determine whether cell fate is dictated by a balanced Myc:Max:Mad network or whether Max is simply a common binding partner for both Myc and Mad. In order to validate the EG mutants in vitro, we have used mouse embryonic fibroblasts derived from a c-Myc ER/ER mouse model generated in our laboratory, in which ER is fused to endogenous c-terminus, allowing Myc to be toggled on and off at will. These cells have to be cultured in the presence of the ER ligand, 4-hydroxytamoxifen (4OHT), so that C-myc is functional and the cells proliferate normally. Whereas MycEG or MaxEG alone are unable to support growth of these cells in the absence of 4OHT, the proliferative arrest phenotype observed without 4OHT is rescued by co-expression of MycEG and MaxEG. We are currently generating mouse models where C-mycEG and MaxEG will replace the endogenous proteins in order to separate the roles of Myc:Max and Mad:Max in development and adult tissues.
Citation Format: Ana Paula Rebocho, Trevor Littlewood, Gerard I. Evan. Disentangling the Myc:Max from the Mad:Max network. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2340. doi:10.1158/1538-7445.AM2014-2340
American Association for Cancer Research (AACR)
Title: Abstract 2340: Disentangling the Myc:Max from the Mad:Max network
Description:
Abstract
The Myc family comprises three basic helix loop helix leucine zipper (bHLHLZ) transcription factors - C-myc, N-myc and L-myc - which regulate a plethora of intra and extracellular processes.
Myc, when bound to Max, another bHLHLZ transcription factor, is able to bind specific DNA sequences, recruit coactivator complexes and promote transcriptional activation.
Max can also promote transcriptional repression by dimerizing with distinct transcription factors such as Mad.
Previous work has shown that Myc expression promotes proliferation whereas Mad expression leads to differentiation, implying that Myc and Mad have opposing roles in cells.
Myc and Mad share the same heterodimeric partner, Max, suggesting that the cell proliferation/differentiation fate is determined by a Myc:Max:Mad network.
To understand how this equilibrium is maintained, we are investigating the effects of separating the Myc:Max from the Mad:Max network.
To separate these networks we have made use of specific Myc and Max mutant proteins in which reciprocal exchanges at the e and g positions of the leucine zipper have been introduced.
Whereas the MycEG and MaxEG proteins dimerize with each other they are unable to associate with their wild type counterparts.
Using these mutants we will determine whether cell fate is dictated by a balanced Myc:Max:Mad network or whether Max is simply a common binding partner for both Myc and Mad.
In order to validate the EG mutants in vitro, we have used mouse embryonic fibroblasts derived from a c-Myc ER/ER mouse model generated in our laboratory, in which ER is fused to endogenous c-terminus, allowing Myc to be toggled on and off at will.
These cells have to be cultured in the presence of the ER ligand, 4-hydroxytamoxifen (4OHT), so that C-myc is functional and the cells proliferate normally.
Whereas MycEG or MaxEG alone are unable to support growth of these cells in the absence of 4OHT, the proliferative arrest phenotype observed without 4OHT is rescued by co-expression of MycEG and MaxEG.
We are currently generating mouse models where C-mycEG and MaxEG will replace the endogenous proteins in order to separate the roles of Myc:Max and Mad:Max in development and adult tissues.
Citation Format: Ana Paula Rebocho, Trevor Littlewood, Gerard I.
Evan.
Disentangling the Myc:Max from the Mad:Max network.
[abstract].
In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA.
Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2340.
doi:10.
1158/1538-7445.
AM2014-2340.
Related Results
<i>MYC</i> rearrangement but not extra <i>MYC</i> copies is an independent prognostic factor in patients with mantle cell lymphoma
<i>MYC</i> rearrangement but not extra <i>MYC</i> copies is an independent prognostic factor in patients with mantle cell lymphoma
Mantle cell lymphoma (MCL) with MYC rearrangement (MYC-R) is rare and little is known about the importance of MYC extra copies (EC) in the absence of MYC-R in MCL patients. This st...
Abstract 4761: Investigation of the role of N-MYC in lung neuroendocrine carcinoma
Abstract 4761: Investigation of the role of N-MYC in lung neuroendocrine carcinoma
Abstract
Small cell lung cancer and large cell neuroendocrine carcinoma are classified as high-grade neuroendocrine tumors of the lung, representing extremely agg...
Improving immunotherapy in high-grade B-cell lymphoma
Improving immunotherapy in high-grade B-cell lymphoma
MYC is a transcription factor that upon deregulation acts as an oncogene. Cancer patients with MYC overexpression face significant worse outcomes to treatment with (immuno)chemothe...
Alternating cycles of quiescent and proliferative cell states determine stemness and leukemia-initiation capacity in acute lymphoblastic leukemia
Alternating cycles of quiescent and proliferative cell states determine stemness and leukemia-initiation capacity in acute lymphoblastic leukemia
Abstract
Background and significance. Stemness in acute myeloid leukemia (AML) is determined by a clonal hierarchy with ...
Flow Cytometry and Cytogenetics of Fine Needle Aspiration Biopsy Samples Is a Reliable Method for Diagnosing Burkitt Lymphoma. Evaluation of 78 Cases from a Single-Institution
Flow Cytometry and Cytogenetics of Fine Needle Aspiration Biopsy Samples Is a Reliable Method for Diagnosing Burkitt Lymphoma. Evaluation of 78 Cases from a Single-Institution
Abstract
Background: The diagnosis of Burkitt lymphoma (BL) is usually based on histopathology (HP), immunohistochemistry (IHC), fluorescence in situ hybridization (...
Abstract 1872: Targeting MYC-driven medulloblastoma using inhibitors of glutamine metabolism.
Abstract 1872: Targeting MYC-driven medulloblastoma using inhibitors of glutamine metabolism.
Abstract
Medulloblastoma is the most common malignant brain tumor in children. Currently, treatment consists of surgical resection, chemotherapy, and whole brain and...
Abstract 1457: NELFE regulates chromatin accessibility to affect MYC induced transcription
Abstract 1457: NELFE regulates chromatin accessibility to affect MYC induced transcription
Abstract
Liver cancer incidence rates have more than tripled in the last 40 years and is projected to increase more than 40% in the next decade. Although progress ha...
Abstract PO-037: Machine learning-enabled transomics identifies three therapeutic targets for MYC-driven diffuse large B cell lymphoma
Abstract PO-037: Machine learning-enabled transomics identifies three therapeutic targets for MYC-driven diffuse large B cell lymphoma
Abstract
MYC activation and dysregulation is a powerful oncogenic driver in multiple cancers, including diffuse large B cell lymphoma (DLBCL). There is a known corre...

